Achievements

2021: Signed total $768m deal to license out gastroesophageal reflux treatment, Fexuprazan to US and China; Completed phase 1 trials of DWP710(stem cell COVID-19 therapy) in Indonesia; US FDA designated DWN12088 as Orphan Drug for Systemic Sclerosis and it is the second time as an orphan drug designation(ODD) since 2019

2020: Developed COVID-19 treatment and selected for a government-sponsored project; Daewoong Pharmaceutical’s Olostar was listed in the 2020 National R&D Excellence Top 100.; Novel diabetes drug Enavogliflozin designated for expedited review for the first time in Korea and conducted a phase 3 clinical trial; Registered as a bio-pharmaceutical accelerator, and sign an MOU with Gyeongsangnam-do, Gimhae, and Inje University; Established iN Therapeutics, a drug discovery company (spun off from Daewoong Pharmaceutical); Selected as a company to be supported by the Ministry of Food and Drug Safety (MDFS) for Quality by Design (QbD); Independently developed botulinum toxin Nabota obtained marketing authorization in Taiwan and Brazil; Obtained halal certification for Easyef Topical Solution and Epodion through Daewoong Infion, a joint venture in Indonesia; Concluded agreements with Mexico and Brazil to export the next-gen gastroesophageal reflux disease drug Fexuprazan; Established AffyXell Therapeutics, a joint venture specializing in cellular therapeutics, with the British biotech company Avacta

2019: Acquired the international standard ISO 9001 certification for a quality management system (QMS); Received the Minister’s Award (Ministry of Science and ICT) as an institute of outstanding research note management; Completed phase-3 clinical trial on Fexuprazan, a next-generation drug for gastroesophageal reflux; Awarded by the government as an outstanding innovative pharmaceutical company; DWN12088, a new drug for pulmonary fibrosis, designated as an orphan drug by the USFDA; Urusa 300mg obtained indication for prevention of postgastrectomy cholelithiasis, being the first in the world; Officially launched Jeuveau, an internally developed botulinum toxin, in the US; Launched Olomax, a compound of three agents (olmesarta, rosuvastatin and amlopidine); Phase-3 clinical trial result of Nabota in the US published in an SCI-grade international journal; DWN12088, a new drug for pulmonary fibrosis, selected for the inter-governmental support project; Internally developed botulinum toxin approved by USFDA, being the first in Asia

2018: Nabota obtained indication for eye wrinkles as the first botulinum toxin in Korea; DWP14012, a new drug for gastroesophageal reflux, selected for inter-governmental support project

2016: Completed construction of the Daewoong Bio Center; Meropenem Inj, an antibiotic, approved by the USFDA

2015: Olostar won the Technology Award for new drug development at the 16th Korea New Drug Award (KNDA); Began joint development in the field of antibody through M&A with HanAll BioPharma

2014: Received a Prime Minister Citation in the science and technology category of the Korea New Growth Management Awards; Won the Technology Award for new drug development at the 15th Korea New Drug Award (KNDA); Nabota selected as a World Class Product of Korea by the Ministry of Trade, Industry and Energy (MOTIE) and the Korea Trade-Investment Promotion Agency (KOTRA); Released Nabota, a botulinum toxin, in Korea; Released Olostar, a new drug compound of olmesartan and rosuvastatin

2012: Caretropin Pen won the 2011-2012 World Star Award; Selected for World Class 300, a global business development project; Selected as an Innovative Pharmaceutical Company

2011: Caretropin Inj. received the Minister’s Award (Ministry of Knowledge Economy)

2008: Easyef acquired the International Nonproprietary Name (INN) certified by the World Health Organization (WHO) as the first in the world

2005: CoenzymeQ10 won the Minister’s Award (Ministry of Health and Welfare) at the Outstanding Technology Contest of the Health Industry Technologies Exposition Korea; CoenzymeQ10 won the Jang Yong-shil Award; Released Luphere, an anticancer agent

2003: Succeeded in developing CoenzymeQ10, being the second in the world; Easyef Topical Solution won second prize at the Korea New Drug Award (Korea Drug Research Association: KNDA)

2002: Easyef Topical Solution awarded as one of 100 Outstanding Patented Products

2001: Released Easyef Topical Solution, Korea’s first new bio-pharmaceutical drug; Acquired the KT (Korea Good Technology) mark for Easyef

1997: Won Outstanding Achievement Award (Korean Intellectual Property Office) for the patented technology of Easyef

1987: Received the Iron Tower Order of Industrial Service Merit in the science and technology category on the 1st Science Day; Acquired the first genetic engineering patent in Korea

Research Result